Abstract: A flexible neuromodulation device and method capable of varying a neuromodulation therapy in order to prevent, delay, or control a sexual emission, and/or increasing an intensity of a sexual climax.

Abstract: A multipoint lock including a pivoting lock bolt including a fixed pivot point and a sliding pivot point, a translating lock bolt, a linkage coupled to and configured to pivot the pivoting lock bolt and to translate the translating lock bolt, an actuation mechanism configured to actuate the linkage and to effect pivoting of the pivoting lock bolt and translation of the translating lock bolt, and an input mechanism configured to receive user input and transmit the user input to the actuation mechanism, the user unput including shifting the input mechanism between an unlocked position and a locked position.

Abstract: A flexible neuromodulation device and method capable of varying a neuromodulation therapy in order to prevent, delay, or control a sexual emission, and/or increasing an intensity of a sexual climax.

Abstract: Apparatus for performing a procedure at a target site of a patient's body, the apparatus comprising: a continuous positive airway pressure (CPAP) apparatus that provides CPAP to the patient's lungs; a medical device for performing the procedure at the target site; and a controller that controls the CPAP apparatus to provide CPAP to the patient's lungs during performance of the procedure.

Abstract: Apparatus for performing a procedure at a target site of a patient's body, the apparatus comprising: a continuous positive airway pressure (CPAP) apparatus that provides CPAP to the patient's lungs; a medical device for performing the procedure at the target site; and a controller that controls the CPAP apparatus to provide CPAP to the patient's lungs during performance of the procedure.

Abstract: A spinal implant including a hollow, generally tubular shell having an exterior lateral surface, a leading end, and a trailing end. The exterior surface includes a plurality of pillars arranged in a non-helical array. Each pillar has a height of 100-4500 microns and a lateral dimension at the widest point of 100-4500 microns. The exterior surface also has a plurality of holes therethrough to permit bone ingrowth therethrough.

Abstract: Methods of treating at least one symptom or condition associated with Anxiety Disorders and/or Mood Disorders comprising administering an effective amount of a compound of Formula I or its pharmaceutically acceptable salt are provided herein.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: 1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative-, Hypnotic- or Anxiolytic-Related Disorders. 2) Attention-Deficit and Disruptive Behavior Disorders. 3) Eating Disorders. 4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. 5) Impulse-Control Disorders, comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: Sleep Disorders including but not limited to 1) Dyssomnia Disorders including but not limited to: a) Primary inomnia, b) Primary Hypersomnia, and c) narcolepsy; and 2) Parasomnias Disorders including but not limited to a) Nightmare Disorder, Sleep Terror Disorder and Sleepwalking Disorder, comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating at least one symptom or condition associated with but not limited to:, Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence including but not limited to Mental Retardation, Learning Disorders, Motor Skills Disorder, Communication Disoorders, Pervasive Developmental Disorders, Attention-Deficit and Disruptive Behavior Disorders, Feeding and Eating Disorders of Infancy or Early Childhood, Tic Disorders, and Elimination Disorders comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: Mood Disorders including but not limited to a) Depressive Disorders, including but not limited to Major Depressive Disorder and Dysthymic Disorder and b) Bipolar Depression and/or Bipolar mania including but not limited to Bipolar I Disorder, including but not limited to those with manic, depressive or mixed episodes, and Bipolar 11 Disorder, c) Cyclothymic Disorder, and d) Mood Disorder Due to a General Medical Condition comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: 1) Schizophrenia and other Psychotic Disorders including but not limited to Psychotic Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and Psychotic Disorder Due to a General Medical Condition and 2) Dementia and other Cognitive Disorders comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating at least one symptom or condition associated with but not limited to: Anxiety Disorders including but not limited to Panic Disorder Without Agoraphobia, Panic Disorder With Agoraphobia, Agoraphobia Without History of Panic Disorder, Specific Phobia, Social Phobia, Obsessive-Compulsive Disorder, Postaumatic Stress Disorder, Acute Stress Disorder, Generalized Anxiety Disorder and Generalized Anxiety Disorder Due to a General Medical Condition comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating anxiety, agitation, hostility, panic, eating disorders, affective symptoms, mood symptoms, negative and positive psychotic symptoms commonly associated with schizophrenia, dementia, anxiety, depression, mood disorders, bipolar disorders, bipolar mania, bipolar depression, cognitive disorders and neurodegenerative disorders comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least on pharmaceutically acceptable carrier or diluent.

Abstract: A method of treating anxiety, agitation, hostility, panic, eating disorders, affective symptoms, mood symptoms, negative and positive psychotic symptoms commonly associated with schizophrenia, dementia, anxiety, depression, mood disorders, bipolar disorders, bipolar mania, bipolar depression, cognitive disorders and neurodegenerative disorders comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least on pharmaceutically acceptable carrier or diluent.

Abstract: A dispensing system for providing a sustained release of fragrance over time by bringing into contact by gravity assistance, mechanical assistance or combination thereof, a discrete, incremental portion of a solid, typically a fragrance-containing solid, and a liquid activator so as to cause sustained, incremental release of the fragrance. The system can additionally a comprise an effervescent component that generates desirable effervescence when the solid is contacted with the liquid activator. Various dispensers and methods that utilize gravity assistance, mechanical assistance or combination thereof can be used to bring the solid and liquid activator into contact to provide this sustained, incremental release of fragrance.

Abstract: A method for treating dyskinesias associated with dopaminergic therapy is described using the a typical antipsychotic agent quetiapine. Also described is the co-administration of quetiapine and a dopaminergic agent for treating Parkinson's disease. Treatment with quetiapine suppresses the symptoms of Parkinson's disease and will attenuate levodopa-induced dyskinetic movements. This allows the dosage of dopaminergic agents, for example levodopa, to be increased without the complicating side-effects normally observed with higher doses.

Abstract: A spinal implant including a hollow, generally tubular shell having an exterior lateral surface, a leading end, and a trailing end. The exterior surface includes a plurality of pillars arranged in a non-helical array. Each pillar has a height of 100-4500 microns and a lateral dimension at the widest point of 100-4500 microns. The exterior surface also has a plurality of holes therethrough to permit bone ingrowth therethrough.

Abstract: A spinal implant including a hollow, generally tubular shell having an exterior lateral surface, a leading end, and a trailing end. The shell has a helical thread projecting from its exterior surface. The thread includes a plurality of pillars. Each pillar has a height of 100-4500 microns and a lateral dimension at the widest point of 100-4500 microns. The exterior surface has a plurality of holes therethrough to permit bone growth therethrough. The spinal implant may alternatively have a plurality of pillars projecting from its exterior surface in a regular, non-helical array.